Brady Collins
Vaccines are a crucial tool in the fight against infectious diseases, and traditional vaccines work by injecting either antigens, attenuated (weakened) or inactivated (dead) viruses into the body to stimulate an antibody response. In recent years, a new type of vaccine that utilizes messenger RNA (mRNA) technology has emerged as a promising alternative. This technology introduces a synthetic fragment of the RNA sequence of a virus into the body, triggering an immune response that prepares the body to fight off future infections. While the COVID-19 pandemic brought mRNA vaccines to the forefront, with the Moderna and Pfizer–BioNTech vaccines demonstrating over 90% efficacy, there is ongoing research into their potential for other diseases. Despite the benefits of mRNA vaccines, such as their rapid development and adaptability to new or mutating viruses, there are concerns about their limitations, particularly regarding respiratory infections and the emergence of new variants. As a result, some countries are shifting their focus to alternative vaccine platforms, such as whole-virus vaccines, while others continue to explore the potential of mRNA technology for diseases beyond COVID-19.
| Characteristics | Values |
|---|---|
| How do mRNA vaccines work? | Vaccines introduce a short-lived synthetically created fragment of the RNA sequence of a virus into the individual being vaccinated. |
| How is it different from traditional vaccines? | Traditional vaccines use either antigens, an attenuated (weakened) virus, an inactivated (dead) virus, or a recombinant antigen-encoding viral vector. |
| What are the limitations of mRNA vaccines? | Vaccines meant to protect against respiratory infections, whether developed through mRNA or older technologies, are generally better at averting severe disease than preventing infection. |
| What are the safety concerns? | People susceptible to an autoimmune response may have an adverse reaction to mRNA vaccines. |
| What are the advantages of mRNA vaccines? | It can be adapted quickly for new or mutating viruses, combined to target multiple variants, and manufactured through a streamlined process that reduces reliance on fragile global supply chains. |
| What are some examples of mRNA vaccines? | Moderna and Pfizer–BioNTech COVID-19 vaccines; Gemcovac, an saRNA Covid vaccine authorised in India in June 2022; ARCT-154, developed by Arcturus Therapeutics. |
| What is the status of mRNA vaccine development? | The US Department of Health and Human Services has decided to terminate 22 mRNA vaccine development investments, citing ineffectiveness against upper respiratory infections like COVID and flu. |
Explore related products
What You'll Learn
How do mRNA vaccines work?
The "m" in mRNA stands for messenger because the vaccine carries instructions for our bodies to make proteins. Scientists figured out how to harness that natural process for vaccines by making mRNA in a lab. They take a snippet of the genetic code that carries instructions for making the protein they want the vaccine to target. Injecting that snippet instructs the body to become its own mini-vaccine factory, making enough copies of the protein for the immune system to recognize and react.
MRNA vaccines are not a “magic force field” that the immune system can use to block an infection, as it can’t detect whether a virus is nearby. It can only respond to a virus that has already entered the body. In the case of COVID-19, this means that the virus could cause an upper respiratory tract infection but would be significantly less likely to cause more severe consequences elsewhere.
Myriad studies on the effectiveness of COVID-19 vaccines have been published since they first became available in late 2020. Although protection does wane over time, they provide the strongest barrier against severe infection and death. For example, a 2024 study by the World Health Organization found that COVID-19 vaccines reduced deaths in the WHO’s European region by at least 57%, saving more than 1.4 million lives since their introduction in December 2020. Another 2022 study, published in The New England Journal of Medicine, reported that two mRNA vaccines were more than 90% effective against COVID-19.
MRNA technology speeds up the vaccine-making process and allows existing vaccines to be updated more quickly. It is a flexible, rapid-response technology that can be reprogrammed for any pathogen once its genetic sequence is known. It is now being tested for personalized cancer vaccines, autoimmune therapies, and treatments for rare diseases. It is also being studied to protect against pathogens like the Nipah, Lassa, and Chikungunya viruses, which could cause the next global emergency.
Pneumonia Vaccine for Seniors: Free or Fee?
You may want to see also
Explore related products
$59.84 $62.99
Pros and cons of mRNA vaccines
The development of vaccines for RNA viruses has been a significant focus area for the scientific community, with mRNA vaccines being one of the key innovations in this field. However, there are differing opinions about the pros and cons of mRNA vaccines.
Pros of mRNA Vaccines:
- Rapid Development and Production: mRNA vaccines can be designed and produced rapidly, making them advantageous for responding to emerging biological threats and pandemics. This technology was instrumental in developing vaccines for COVID-19 within a short timeframe.
- Adaptability: mRNA vaccines can be easily modified to address new variants and mutated strains of viruses. This adaptability is crucial in the ongoing battle against rapidly evolving pathogens.
- Safety and Effectiveness: Infectious disease experts and studies have indicated that mRNA vaccines are safe and effective. The technology has undergone rigorous trials, meeting the same safety and effectiveness standards as other vaccines.
- Platform for Innovation: mRNA technology is not limited to COVID-19; it opens doors to faster and more precise vaccine development for other diseases, including the flu, RSV, and cancer therapies.
- Protection Against Severe Disease: While respiratory vaccines may not always prevent infection, mRNA vaccines can help reduce the chances of virus replication and lower the risk of severe disease.
Cons of mRNA Vaccines:
- Regulatory Hurdles: mRNA vaccines are considered "next-generation vaccines," and as a result, they may face significant regulatory challenges before being approved for human use.
- Poor Protective Immune Response: Since mRNA vaccines only allow for a fragment of the virus to be introduced, they may prompt a weaker immune response, requiring multiple booster shots.
- Theoretical Genome Integration: There is a theoretical possibility that vaccine mRNA could integrate into an individual's genome, although this has not been proven.
- Upper Respiratory Infections: Critics argue that mRNA vaccines are ineffective against upper respiratory infections like COVID-19 and the flu. They claim that these vaccines fail to protect against these specific viruses and that safer alternatives should be pursued.
The debate surrounding mRNA vaccines highlights the complexities in vaccine development and the ongoing pursuit of optimal solutions to protect public health.
Hepatitis B Vaccines for Infants: Are They Mandatory in Bunei?
You may want to see also
Explore related products
$11.67 $21.99
The future of mRNA vaccines
MRNA vaccines have several advantages over traditional vaccines. Firstly, they have rapid development and production times, making them ideal for responding to new and emerging infectious diseases and their variants. Secondly, they are "plug-and-play" vaccines, which means they use a genetic code to instruct the body's cells to produce proteins that train the immune system, rather than using a weakened or dead version of the virus. This results in lower costs and faster development times.
Penn Medicine researchers have developed an mRNA-based vaccine against all 20 known subtypes of the influenza virus. This universal flu vaccine, if successful in clinical trials, could provide a baseline level of immune memory against diverse flu strains and protect against future flu pandemics. Additionally, researchers are working on mRNA vaccines for other diseases, such as leptospirosis, a bacterial disease common in Southeast Asia, and malaria.
Despite the promising future of mRNA vaccines, there have been concerns about funding and support. In 2025, the U.S. Department of Health and Human Services announced the cancellation of contracts and the withdrawal of nearly $500 million in funding for mRNA vaccine development projects, particularly those targeting respiratory viruses like COVID-19 and the flu. This decision has sparked criticism and concerns among experts, who worry about the impact on cancer treatments and the country's ability to respond to future biological threats.
However, some critics argue that the focus should be on developing "safer, broader vaccine strategies" and "universal vaccines" that mimic natural immunity. While mRNA technology has proven safe and effective, with mild and short-lived side effects, critics argue that it is time to explore alternative approaches.
In conclusion, mRNA vaccines have revolutionized the field of medicine and have the potential to make significant strides in the treatment and prevention of countless diseases. While there may be shifts in funding and research priorities, the flexibility and rapid-response capabilities of mRNA technology position it as a powerful tool in the ongoing battle against infectious diseases and future pandemics.
Chickenpox Vaccine: When Did It Start?
You may want to see also
Explore related products
mRNA vaccines vs traditional vaccines
The emergence of messenger RNA (mRNA) technology has revolutionized the landscape of vaccine development, particularly highlighted during the COVID-19 pandemic.
MRNA vaccines are formed from the messenger RNA of the virus. They contain genetic material that tells the body how to make a protein that produces immunity against specific microbes. This protein causes an immune response, which teaches the body how to protect itself from a specific virus. For example, the SARS-CoV-2 virus has spike proteins on its surface. Once administered, the mRNA strands enter human cells and instruct them to produce these viral proteins, prompting an immune response. mRNA vaccines do not contain any live microbes, and therefore cannot transmit any infection. They also do not change a person's DNA.
Traditional vaccines, on the other hand, use weakened or dead microbes, or pieces of them, to stimulate immunity. The exact mechanism depends on the type of vaccine. Live vaccines use a weakened form of a microbe that causes an infection. The immune system responds to these weakened microbes, producing strong and lasting protection against future infections. Many live vaccines provide lifelong protection from a certain infection. However, because they contain a small amount of live virus, they may not be suitable for people with weakened immune systems. Inactivated vaccines, another type of traditional vaccine, use dead microbes rather than live ones. They do not offer as much protection as live microbes, so booster shots may be necessary to produce ongoing immunity. Traditional vaccines have been used for many years to vaccinate against diseases such as polio, measles, and influenza.
MRNA vaccines have several advantages over traditional vaccines. They have a shorter manufacturing time and do not require adjuvants, which are substances that enhance the body's immune response to an antigen. They also have very few risks and do not require live virus production. However, one potential drawback is the need for ultra-cold storage. Traditional vaccines, on the other hand, have the advantage of providing lifelong immunity against certain infections.
Federal Employees: Mandatory Vaccination Requirements?
You may want to see also
Explore related products
The development of mRNA vaccines
The advantages of this technology are its speed and adaptability. For instance, during the COVID-19 pandemic, the genetic sequence of the SARS-CoV-2 virus was identified within a week or two of the outbreak, which was all that was needed to make an mRNA vaccine. This speed is crucial in responding to emerging pathogens, particularly those that evolve quickly. The mRNA vaccines for COVID-19 were also highly effective at preventing severe disease and were proven to be extremely safe.
MRNA vaccines have been hailed as a strategic asset, with the ability to rapidly design, produce, and deploy medical countermeasures, which is vital for national defence against biological threats. This technology has been so successful that global organisations such as the World Health Organization and the Bill & Melinda Gates Foundation have committed substantial resources to advance its development.
However, despite the success and promise of mRNA vaccines, there has been some controversy and pushback. In 2025, the US Department of Health and Human Services (HHS) announced it would wind down 22 mRNA vaccine development projects, totalling around $500 million in investments. This decision was based on the belief that these vaccines are ineffective against upper respiratory infections and that safer, broader vaccine platforms are needed to address the limitations of mRNA vaccines.
The decision to cut funding for mRNA vaccine development has been criticised by some, who argue that it is a tragic loss of a lifesaving technology with huge potential. They argue that mRNA vaccines have been proven safe and effective, and the limitations can be addressed through improvement rather than abandonment.
Uber Australia: Vaccination Requirements for Drivers
You may want to see also
Frequently asked questions
RNA vaccines are a new type of vaccine that uses a molecule called messenger RNA (mRNA) rather than a part of an actual bacteria or virus.
RNA vaccines introduce a short-lived synthetically created fragment of the RNA sequence of a virus into the individual being vaccinated. The dendritic cells in our body use their internal machinery (ribosomes) to read the mRNA and produce the viral antigens that the mRNA encodes.
Examples of RNA vaccines include the COVID-19 vaccines from Moderna and Pfizer–BioNTech, which had short-term efficacy rates of over 90% against the original SARS-CoV-2 virus. The first saRNA Covid vaccine authorised was Gemcovac, in India in June 2022.
RNA vaccines can be adapted quickly for new or mutating viruses, combined to target multiple variants, and manufactured through a streamlined process that reduces reliance on global supply chains. They are also effective in stimulating long-term protection, often requiring just a single dose.
